Abcellera Biologics Inc
NASDAQ:ABCL
US |
Fubotv Inc
NYSE:FUBO
|
Media
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
US |
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
|
CN |
NIO Inc
NYSE:NIO
|
Automobiles
|
|
US |
Fluor Corp
NYSE:FLR
|
Construction
|
|
US |
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
|
US |
TopBuild Corp
NYSE:BLD
|
Consumer products
|
|
US |
Abbott Laboratories
NYSE:ABT
|
Health Care
|
|
US |
Chevron Corp
NYSE:CVX
|
Energy
|
|
US |
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
|
US |
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
|
US |
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
|
US |
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
|
US |
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
2.39
5.97
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
Fubotv Inc
NYSE:FUBO
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
C
|
C3.ai Inc
NYSE:AI
|
US |
Uber Technologies Inc
NYSE:UBER
|
US | |
NIO Inc
NYSE:NIO
|
CN | |
Fluor Corp
NYSE:FLR
|
US | |
Jacobs Engineering Group Inc
NYSE:J
|
US | |
TopBuild Corp
NYSE:BLD
|
US | |
Abbott Laboratories
NYSE:ABT
|
US | |
Chevron Corp
NYSE:CVX
|
US | |
Occidental Petroleum Corp
NYSE:OXY
|
US | |
Matrix Service Co
NASDAQ:MTRX
|
US | |
Automatic Data Processing Inc
NASDAQ:ADP
|
US | |
Qualcomm Inc
NASDAQ:QCOM
|
US | |
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one ABCL stock under the Base Case scenario is 1.92 USD. Compared to the current market price of 2.66 USD, Abcellera Biologics Inc is Overvalued by 28%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Abcellera Biologics Inc
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for ABCL cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Abcellera Biologics Inc
Balance Sheet Decomposition
Abcellera Biologics Inc
Current Assets | 742.9m |
Cash & Short-Term Investments | 643.1m |
Receivables | 63.2m |
Other Current Assets | 36.5m |
Non-Current Assets | 649.9m |
Long-Term Investments | 84.1m |
PP&E | 331.3m |
Intangibles | 100.4m |
Other Non-Current Assets | 134.2m |
Current Liabilities | 79.6m |
Accounts Payable | 34.8m |
Accrued Liabilities | 11.1m |
Other Current Liabilities | 33.7m |
Non-Current Liabilities | 235.2m |
Other Non-Current Liabilities | 235.2m |
Earnings Waterfall
Abcellera Biologics Inc
Revenue
|
33m
USD
|
Operating Expenses
|
-341m
USD
|
Operating Income
|
-308.1m
USD
|
Other Expenses
|
132.3m
USD
|
Net Income
|
-175.8m
USD
|
Free Cash Flow Analysis
Abcellera Biologics Inc
USD | |
Free Cash Flow | USD |
ABCL Profitability Score
Profitability Due Diligence
Abcellera Biologics Inc's profitability score is 23/100. The higher the profitability score, the more profitable the company is.
Score
Abcellera Biologics Inc's profitability score is 23/100. The higher the profitability score, the more profitable the company is.
ABCL Solvency Score
Solvency Due Diligence
Abcellera Biologics Inc's solvency score is 64/100. The higher the solvency score, the more solvent the company is.
Score
Abcellera Biologics Inc's solvency score is 64/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
ABCL Price Targets Summary
Abcellera Biologics Inc
According to Wall Street analysts, the average 1-year price target for ABCL is 15.74 USD with a low forecast of 5.05 USD and a high forecast of 29.4 USD.
Dividends
Current shareholder yield for ABCL is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Profile
Country
Industry
Market Cap
Dividend Yield
Description
AbCellera Biologics, Inc. engages in the development of therapeutic antibodies. The company is headquartered in Vancouver, British Columbia and currently employs 386 full-time employees. The company went IPO on 2020-12-11. AbCellera's full-stack, artificial intelligence (AI)-powered drug discovery platform integrates technologies from engineering, microfluidics, single-cell analysis, high-throughput genomics, machine learning, and hyper-scale data science. AbCellera partners with drug developers of all sizes, from large pharmaceutical to small biotechnology companies, enabling them to tackle the toughest problems in drug development.
Contact
IPO
Employees
Officers
The intrinsic value of one ABCL stock under the Base Case scenario is 1.92 USD.
Compared to the current market price of 2.66 USD, Abcellera Biologics Inc is Overvalued by 28%.